Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...
Allie Reece has shared her cancer journey on TikTok, where she has built a supportive community of thousands of followers ...
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News CommentaryVANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is ...
A BRAVE cancer fighter who is currently in remission after his third bout of the disease is undergoing gruelling treatment ahead of a donor ...
The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
A recent analysis found a much higher major infection rate in patients receiving a liberalized diet vs a neutropenic diet, ...
We report the case of a 17-year-old adolescent presenting with a large pineal region mass initially interpreted as a ruptured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback